Pharmacogenomics: questions and concerns.

Area of Science:

• Pharmacogenomics and Personalized Medicine
• Healthcare Economics
• Bioethics and Law

Background:

• Aging populations and rising healthcare costs necessitate innovative, cost-effective medical treatments.
• Adverse drug reactions contribute significantly to healthcare expenditure.
• Public acceptance of pharmacogenomics is high due to its potential for personalized, safer, and more affordable treatments.

Purpose of the Study:

• To explore the potential of pharmacogenomics in addressing healthcare cost pressures.
• To highlight the role of genetic polymorphisms in individual drug responses.
• To identify and address the ethical, social, and legal concerns associated with pharmacogenomics.

Main Methods:

• Review of current literature on pharmacogenomics and healthcare economics.
• Analysis of genetic polymorphisms influencing drug response variability.
• Examination of ethical, social, and legal implications of pharmacogenomic implementation.

Main Results:

• Pharmacogenomics promises individualized drug therapy, enhancing efficacy and safety.
• Genetic variations explain differences in patient responses to medications.
• Significant ethical, social, and legal challenges require international regulatory attention.

Conclusions:

• Pharmacogenomics presents a viable strategy for cost containment in healthcare.
• Robust international regulations are crucial to mitigate risks of discrimination and harm.
• Proactive ethical and legal frameworks are essential for responsible pharmacogenomic advancement.